Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

OCUL Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.50%

Insider Buying (Last 12 Months): $6,999,999.52

Insider Selling (Last 12 Months): $224,666.50

Ocular Therapeutix Insider Trading History Chart

Ocular Therapeutix Share Price & Price History

^$10.78

▼ -0.16 (-1.46%)

As of 11/7/2024 01:00 AM ET

Days: 30 | 90 | 365

The Crypto That’s Making Wall Street Sweat

From Crypto 101 Media | Ad

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Ocular Therapeutix Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2024	Sanjay Nayak	Insider	Sell	1,832	$9.02	$16,524.64	176,194
5/23/2024	Sanjay Nayak	Insider	Sell	2,274	$5.84	$13,280.16	178,026
2/26/2024	Summer Road Llc	Major Shareholder	Buy	930,851	$7.52	$6,999,999.52	8,591,401
1/31/2024	Antony C. Mattessich	CEO	Sell	18,338	$4.95	$90,773.10	427,943
1/31/2024	Donald Notman	CFO	Sell	6,433	$4.95	$31,843.35	139,932
1/31/2024	Philip C Strassburger	General Counsel	Sell	6,831	$4.95	$33,813.45	109,218
1/31/2024	Rabia Gurses Ozden	Insider	Sell	7,764	$4.95	$38,431.80	92,767
8/30/2023	Antony C. Mattessich	CEO	Buy	6,500	$3.81	$24,765.00	6,500
7/7/2023	Rabia Gurses Ozden	Insider	Sell	832	$4.93	$4,101.76	100,531
2/6/2023	Antony C. Mattessich	CEO	Sell	19,669	$4.24	$83,396.56	446,281
2/6/2023	Christopher G White	Insider	Sell	5,829	$4.24	$24,714.96	94,766
2/6/2023	Donald Notman	CFO	Sell	6,476	$4.24	$27,458.24	139,387
2/6/2023	Philip C Strassburger	General Counsel	Sell	6,181	$4.24	$26,207.44	109,071
11/7/2022	Summer Road Llc	Major Shareholder	Buy	7,328	$3.50	$25,648.00	6,122,089
10/10/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$4.00	$40,000.00	6,104,761
9/29/2022	Summer Road Llc	Major Shareholder	Buy	18,800	$4.04	$75,952.00	6,094,761
9/27/2022	Summer Road Llc	Major Shareholder	Buy	130,000	$4.68	$608,400.00	6,074,761
2/23/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$4.80	$48,000.00
2/18/2022	Summer Road Llc	Major Shareholder	Buy	40,000	$5.00	$200,000.00
1/27/2022	Summer Road Llc	Major Shareholder	Buy	1,477	$5.20	$7,680.40
1/24/2022	Summer Road Llc	Major Shareholder	Buy	44,400	$5.31	$235,764.00
1/20/2022	Summer Road Llc	Major Shareholder	Buy	17,948	$5.70	$102,303.60
1/18/2022	Summer Road Llc	Major Shareholder	Buy	6,807	$6.00	$40,842.00
1/13/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$6.20	$62,000.00
12/15/2021	Summer Road Llc	Major Shareholder	Buy	15,000	$6.22	$93,300.00
12/13/2021	Summer Road Llc	Major Shareholder	Buy	10,510	$6.50	$68,315.00
12/10/2021	Summer Road Llc	Major Shareholder	Buy	30,000	$6.65	$199,500.00
12/8/2021	Summer Road Llc	Major Shareholder	Buy	5,300	$6.75	$35,775.00
12/6/2021	Summer Road Llc	Major Shareholder	Buy	55,600	$6.13	$340,828.00

The secret supplier behind NVIDIA, Tesla and Microsoft

From Behind the Markets | Ad

The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.

Click here for the ticker >>>

SEC Filings (Institutional Ownership Changes) for Ocular Therapeutix (NASDAQ:OCUL)

59.21% of Ocular Therapeutix stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ocular Therapeutix Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/5/2024	GSA Capital Partners LLP	126,681	$1.10M	0.1%	N/A	0.081%
11/1/2024	Capital Performance Advisors LLP	8,034	$70K	0.0%	N/A	0.005%
10/31/2024	Principal Financial Group Inc.	14,561	$0.13M	0.0%	-44.8%	0.009%
10/30/2024	Rosalind Advisors Inc.	885,000	$7.70M	4.8%	+18.0%	0.568%
10/25/2024	Deltec Asset Management LLC	2,600,073	$22.62M	4.5%	+0.4%	1.668%
10/25/2024	China Universal Asset Management Co. Ltd.	29,989	$0.26M	0.0%	+64.8%	0.019%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	5,639	$49K	0.0%	+22.0%	0.004%
10/23/2024	Assenagon Asset Management S.A.	2,825,756	$24.58M	0.0%	N/A	1.812%
10/16/2024	Nottingham Advisors Inc.	185,766	$1.62M	0.2%	-3.9%	0.120%
10/11/2024	Creative Planning	20,947	$0.18M	0.0%	N/A	0.013%
10/10/2024	Essex Investment Management Co. LLC	443,677	$3.86M	0.7%	+0.3%	0.286%
10/7/2024	Diversified Trust Co	12,239	$0.11M	0.0%	N/A	0.008%
10/3/2024	SG Americas Securities LLC	45,187	$0.39M	0.0%	N/A	0.029%
8/22/2024	Cetera Investment Advisers	739,044	$5.06M	0.0%	+1.8%	0.477%
8/20/2024	Nantahala Capital Management LLC	1,000,000	$6.84M	0.4%	N/A	0.646%
8/19/2024	Point72 Asset Management L.P.	2,706,663	$18.51M	0.0%	N/A	1.736%
8/16/2024	Second Line Capital LLC	262,810	$1.80M	0.6%	N/A	0.170%
8/16/2024	Algert Global LLC	10,114	$69K	0.0%	N/A	0.007%
8/15/2024	The Manufacturers Life Insurance Company	116,964	$0.80M	0.0%	+61.5%	0.076%
8/15/2024	Dark Forest Capital Management LP	12,383	$85K	0.0%	-39.3%	0.008%
8/14/2024	Squarepoint Ops LLC	64,911	$0.44M	0.0%	+275.3%	0.042%
8/14/2024	Marshall Wace LLP	429,592	$2.94M	0.0%	N/A	0.277%
8/14/2024	Logos Global Management LP	5,150,000	$35.23M	2.8%	-11.4%	3.325%
8/14/2024	Paradigm Capital Management Inc. NY	300,000	$2.05M	0.1%	+114.3%	0.194%
8/14/2024	Tri Locum Partners LP	514,642	$3.52M	0.9%	N/A	0.332%
8/14/2024	Avoro Capital Advisors LLC	8,060,000	$55.13M	0.7%	+12.7%	5.204%
8/14/2024	HighVista Strategies LLC	61,859	$0.42M	0.2%	N/A	0.040%
8/14/2024	ProShare Advisors LLC	25,049	$0.17M	0.0%	-12.1%	0.016%
8/14/2024	Profund Advisors LLC	43,182	$0.30M	0.0%	+263.9%	0.028%
8/12/2024	Amalgamated Bank	5,384	$37K	0.0%	+37.9%	0.003%
8/5/2024	Arizona State Retirement System	28,151	$0.19M	0.0%	N/A	0.018%
8/5/2024	Victory Capital Management Inc.	17,403	$0.12M	0.0%	+36.9%	0.011%
8/3/2024	TD Asset Management Inc	112,800	$0.77M	0.0%	+40.3%	0.073%
8/1/2024	Rhumbline Advisers	211,301	$1.45M	0.0%	+39.1%	0.136%
7/31/2024	Aptus Capital Advisors LLC	262,810	$1.80M	0.0%	N/A	0.170%
7/30/2024	Atlas Capital Advisors LLC	5,000	$34K	0.0%	N/A	0.003%
7/29/2024	Principal Financial Group Inc.	26,364	$0.18M	0.0%	-5.4%	0.017%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	32,044	$0.22M	0.0%	+757.9%	0.021%
7/29/2024	Banco Santander S.A.	377,368	$2.58M	0.0%	+81.3%	0.244%
7/26/2024	Bank of New York Mellon Corp	495,635	$3.39M	0.0%	+49.6%	0.320%
7/16/2024	Deltec Asset Management LLC	2,590,265	$17.72M	3.4%	+9.6%	1.672%
7/12/2024	Rosalind Advisors Inc.	750,000	$5.13M	3.8%	N/A	0.484%
7/9/2024	Dudley & Shanley Inc.	16,200	$0.11M	0.0%	N/A	0.010%
5/29/2024	Opaleye Management Inc.	6,653,138	$60.54M	13.2%	+9.6%	4.295%
5/24/2024	Cetera Advisors LLC	723,490	$6.58M	0.1%	+1,455.0%	0.467%
5/24/2024	Cetera Investment Advisers	725,990	$6.61M	0.0%	+6.5%	0.469%
5/16/2024	Bayesian Capital Management LP	10,304	$94K	0.0%	N/A	0.007%
5/15/2024	Price T Rowe Associates Inc. MD	662,672	$6.03M	0.0%	+1,142.3%	0.428%
5/15/2024	Avoro Capital Advisors LLC	7,148,936	$65.06M	0.8%	N/A	4.615%
5/14/2024	EntryPoint Capital LLC	15,312	$0.14M	0.1%	N/A	0.010%
5/14/2024	American International Group Inc.	56,981	$0.52M	0.0%	+43.4%	0.037%
5/13/2024	Ameritas Investment Partners Inc.	11,531	$0.11M	0.0%	+39.4%	0.007%
5/10/2024	Vanguard Group Inc.	7,235,131	$65.84M	0.0%	+41.4%	4.676%
5/10/2024	Banco Santander S.A.	208,196	$1.90M	0.0%	-61.5%	0.135%
5/8/2024	ProShare Advisors LLC	28,498	$0.26M	0.0%	+55.7%	0.018%
5/7/2024	SG Americas Securities LLC	28,946	$0.26M	0.0%	+47.3%	0.019%
5/6/2024	Quantbot Technologies LP	46,500	$0.42M	0.0%	N/A	0.030%
5/3/2024	Essex Investment Management Co. LLC	376,200	$3.42M	0.7%	+1.6%	0.243%
5/1/2024	BNP Paribas Financial Markets	185,308	$1.69M	0.0%	+373.1%	0.120%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	53,456	$0.49M	0.0%	N/A	0.035%
4/29/2024	Principal Financial Group Inc.	27,880	$0.25M	0.0%	+27.0%	0.018%
4/29/2024	China Universal Asset Management Co. Ltd.	21,199	$0.19M	0.0%	+130.6%	0.014%
4/24/2024	Simplicity Wealth LLC	28,987	$0.26M	0.0%	N/A	0.019%
4/17/2024	Deltec Asset Management LLC	2,364,084	$21.51M	4.2%	-3.3%	1.591%
3/8/2024	Trust Co. of Vermont	6,000	$27K	0.0%	+20.0%	0.008%
2/26/2024	Virtu Financial LLC	62,066	$0.28M	0.0%	N/A	0.078%
2/15/2024	Opaleye Management Inc.	6,070,000	$27.07M	7.3%	-6.2%	7.643%
2/15/2024	Great Point Partners LLC	700,000	$3.12M	0.5%	N/A	0.881%
2/14/2024	Artia Global Partners LP	440,000	$1.96M	0.6%	N/A	0.554%
2/13/2024	Aristides Capital LLC	50,226	$0.22M	0.1%	N/A	0.063%
2/13/2024	Tower Research Capital LLC TRC	9,756	$44K	0.0%	+142.3%	0.012%
2/9/2024	Franklin Resources Inc.	4,500,159	$20.07M	0.0%	N/A	5.666%
2/8/2024	Essex Investment Management Co. LLC	370,372	$1.65M	0.3%	N/A	0.466%
2/7/2024	Ieq Capital LLC	30,129	$0.13M	0.0%	-64.4%	0.038%
2/5/2024	Victory Capital Management Inc.	10,135	$45K	0.0%	N/A	0.013%
1/29/2024	Simplicity Solutions LLC	44,987	$0.20M	0.0%	N/A	0.057%
1/24/2024	China Universal Asset Management Co. Ltd.	9,192	$41K	0.0%	+350.6%	0.012%
1/22/2024	Deltec Asset Management LLC	2,443,607	$10.90M	2.5%	+18.5%	3.077%
1/18/2024	Relyea Zuckerberg Hanson LLC	17,600	$78K	0.0%	N/A	0.022%
1/16/2024	Raymond James Financial Services Advisors Inc.	62,040	$0.28M	0.0%	-16.6%	0.078%
1/16/2024	Raymond James & Associates	129,012	$0.58M	0.0%	+7.0%	0.162%
1/16/2024	Legato Capital Management LLC	149,515	$0.67M	0.1%	N/A	0.188%
1/12/2024	SG Americas Securities LLC	19,646	$88K	0.0%	+60.5%	0.025%
12/6/2023	Citigroup Inc.	20,132	$63K	0.0%	-44.3%	0.025%
11/22/2023	Graham Capital Management L.P.	95,363	$0.30M	0.0%	N/A	0.120%
11/15/2023	GSA Capital Partners LLP	233,582	$0.73M	0.1%	+96.4%	0.294%
11/15/2023	Sectoral Asset Management Inc.	969,350	$3.04M	0.6%	+20.8%	1.221%
11/14/2023	Profund Advisors LLC	20,827	$65K	0.0%	+94.1%	0.026%
11/13/2023	Algert Global LLC	25,480	$80K	0.0%	-48.2%	0.032%
11/13/2023	Paradigm Capital Management Inc. NY	80,000	$0.25M	0.0%	+100.0%	0.101%
11/13/2023	Rafferty Asset Management LLC	11,837	$37K	0.0%	N/A	0.015%
11/7/2023	New York State Common Retirement Fund	31,521	$99K	0.0%	+229.0%	0.040%
11/7/2023	Barclays PLC	25,963	$81K	0.0%	+22.9%	0.033%
10/31/2023	Levin Capital Strategies L.P.	22,500	$71K	0.0%	-30.8%	0.028%
10/26/2023	Emerald Advisers LLC	20,768	$65K	0.0%	-54.6%	0.026%
10/24/2023	Bank of New York Mellon Corp	240,310	$0.76M	0.0%	-18.1%	0.303%
10/24/2023	Raymond James Financial Services Advisors Inc.	74,401	$0.23M	0.0%	+46.6%	0.094%
10/24/2023	Raymond James & Associates	120,561	$0.38M	0.0%	+155.2%	0.152%
10/23/2023	Deltec Asset Management LLC	2,061,797	$6.47M	1.5%	+4.4%	2.597%
10/13/2023	SG Americas Securities LLC	12,242	$38K	0.0%	N/A	0.015%

Data available starting January 2016

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $10.78

$10.53

$11.07

50 Day Range

MA: $9.66

$8.35

$11.47

52 Week Range

Now: $10.78

$2.00

$11.77

Volume

825,068 shs

Average Volume

1,884,922 shs

Market Capitalization

$1.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Ocular Therapeutix?: Ocular Therapeutix's top insider investors include:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Sanjay Nayak (Insider)
Donald Notman (CFO)
Philip C Strassburger (General Counsel)
Rabia Gurses Ozden (Insider)
Christopher G White (Insider)
Learn More about top insider investors at Ocular Therapeutix.
Who are the major institutional investors of Ocular Therapeutix?: Ocular Therapeutix's top institutional investors include:
Assenagon Asset Management S.A. — 1.81%
Deltec Asset Management LLC — 1.67%
Rosalind Advisors Inc. — 0.57%
Essex Investment Management Co. LLC — 0.29%
Nottingham Advisors Inc. — 0.12%
GSA Capital Partners LLP — 0.08%
Learn More about top institutional investors of Ocular Therapeutix stock.
Which major investors are selling Ocular Therapeutix stock?: In the previous quarter, OCUL stock was sold by these institutional investors:
Principal Financial Group Inc.
Nottingham Advisors Inc.
Within the last year, company insiders that have sold Ocular Therapeutix company stock include:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Sanjay Nayak (Insider)
Donald Notman (CFO)
Philip C Strassburger (General Counsel)
Learn More investors selling Ocular Therapeutix stock.
Which major investors are buying Ocular Therapeutix stock?: During the previous quarter, OCUL stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Rosalind Advisors Inc.
GSA Capital Partners LLP
SG Americas Securities LLC
Creative Planning
Diversified Trust Co
China Universal Asset Management Co. Ltd.
Deltec Asset Management LLC
During the previous year, these company insiders have bought Ocular Therapeutix stock:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Learn More investors buying Ocular Therapeutix stock.

625,000% Gain

From Crypto Swap Profits | Ad

>> Dive into the Workshop Here